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Background: The innate immune system contributes to the outcome after stroke, where neuroinflammation and
post-stroke systemic immune depression are central features. Tumor necrosis factor (TNF), which exists in both a
transmembrane (tm) and soluble (sol) form, is known to sustain complex inflammatory responses associated with
stroke. We tested the effect of systemically blocking only solTNF versus blocking both tmTNF and solTNF on infarct
volume, functional outcome and inflammation in focal cerebral ischemia.
Methods: We used XPro1595 (a dominant-negative inhibitor of solTNF) and etanercept (which blocks both solTNF
and tmTNF) to test the effect of systemic administration on infarct volume, functional recovery and inflammation
after focal cerebral ischemia in mice. Functional recovery was evaluated after one, three and five days, and infarct
volumes at six hours, 24 hours and five days after ischemia. Brain inflammation, liver acute phase response (APR),
spleen and blood leukocyte profiles, along with plasma microvesicle analysis, were evaluated.
Results: We found that both XPro1595 and etanercept significantly improved functional outcomes, altered
microglial responses, and modified APR, spleen T cell and microvesicle numbers, but without affecting infarct
volumes.
Conclusions: Our data suggest that XPro1595 and etanercept improve functional outcome after focal cerebral
ischemia by altering the peripheral immune response, changing blood and spleen cell populations and decreasing
granulocyte infiltration into the brain. Blocking solTNF, using XPro1595, was just as efficient as blocking both
solTNF and tmTNF using etanercept. Our findings may have implications for future treatments with anti-TNF drugs
in TNF-dependent diseases.
Keywords: SolTNF and tmTNF, Granulocytes, Behavior, Acute phase response, Microvesicle, InflammationBackground
Tumor necrosis factor (TNF) is an immunomodulatory
molecule known to be implicated in central nervous sys-
tem (CNS) insults such as stroke [1]. Immune responses
within the CNS, as well as systemic inflammatory events,
play important roles in the progression, repair and re-
covery of stroke, offering new immune-based approaches* Correspondence: klambertsen@health.sdu.dk
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unless otherwise stated.as future treatment strategies in stroke patients. TNF is
present in low concentrations in normal brain tissue and
upregulated after ischemia [1]. It exists both as trans-
membrane (tm)TNF and soluble (sol)TNF. tmTNF acts
through cell-to-cell contact to promote juxtacrine signal-
ing and is important for cellular communication in the
innate immune system [2], but also for functional recov-
ery and axonal preservation [3], whereas solTNF acts in
a paracrine manner and is an important mediator of
both acute and chronic inflammation [4].
Anti-TNF therapies such as etanercept, which blocks
both solTNF and tmTNF, are currently used to treatl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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lieve fatigue and symptoms of depression associated with
chronic diseases [5]. Furthermore, peri-spinal etanercept
has been used with success in stroke and traumatic brain
injury patients, where treatment resulted in neurological
improvement [7,8]. However, their use is hampered by
side effects, including increased risk of sepsis, demyelin-
ating disease, neuropathies, heart failure and also infec-
tions [9], which represents a considerable risk for stroke
patients. Since etanercept inhibits both solTNF and
tmTNF, this raises the possibility that solTNF-specific
inhibitors, sparing tmTNF, have the potential to inhibit
deleterious inflammation without compromising the im-
mune system’s response to infections. XPro1595, an
engineered dominant-negative TNF that inactivates only
solTNF [10], has proven to be effective in animal models
of CNS disorders involving increased TNF production
[3,11,12], and in attenuating experimental arthritis [13]
and endotoxin-induced liver injury [14], without sup-
pressing the innate immunity to infection, in contrast to
etanercept treatment. The ability of XPro1595 to be
tmTNF-sparing and solTNF-selective potentially makes
XPro1595 a safer clinical drug than etanercept as it en-
sures that the role of tmTNF in immune function and
myelin preservation is not compromised.
In the present study, we used etanercept and XPro1595
to test the effect of systemic administration on functional
recovery, infarct volume, and systemic and central inflam-
matory responses in a murine model of focal cerebral
ischemia.
Materials and methods
Animals
Adult male C57BL/6 mice (between seven and eight
weeks of age, n = 256) were purchased from Taconic Ltd.
(Ry, Denmark) and transferred to the Laboratory of
Biomedicine, University of Southern Denmark, where
they were allowed to acclimatize for seven days prior to
surgery. Animals were housed under diurnal lighting
conditions and given free access to food and water. All
animal experiments were performed in accordance with
the relevant guidelines and regulations approved by the
Danish Animal Ethical Committee (numbers 2011/561-
1950 and 2013-15-2934-00924).
Induction of permanent middle cerebral artery occlusion
The distal part of the left middle cerebral artery (MCA)
was permanently occluded [15] under Hypnorm and
Dormicum anesthesia (fentanyl citrate (0.315 mg/ml;
Jansen-Cilag) and fluanisone (10 mg/ml; Jansen-Cilag,
Birkerød, Denmark), and midazolam (5 mg/ml; Hoffmann-
La Roche, Hvidovre, Denmark)), respectively. After surgery,
mice were injected subcutaneously with 1 ml of 0.9% saline
and allowed to recover in a 25°C controlled environment.Mice surviving for five days were returned to the con-
ventional animal facility after 24 hours. For post-surgical
analgesia, mice were treated with 0.001 mg/20 g buprenor-
phine hydrochloride (Temgesic, Schering-Plough, Ballerup,
Denmark) three times at eight-hour intervals, starting im-
mediately prior to surgery.
Group size and study design
The size of the ischemic infarct was measured in three
separate randomized, double-blinded, vehicle-controlled
studies in mice allowed to survive for six hours (n = 30),
24 hours (n = 60) and five days (n = 74) after induction of
permanent middle cerebral artery occlusion (pMCAO). In
order to evaluate the effect of ischemia on functional out-
come and the acute phase response (APR), a group of
sham-treated mice were included at all time points (total
n = 35). Furthermore, un-manipulated controls were in-
cluded in flow cytometric and microparticle analyses (total
n = 27). A total of 12 mice were excluded due to lack of in-
farct in mice subjected to pMCAO or presence of unin-
tended infarcts in shams. Mortality was 1.8% and there
were no differences in mortality between the different
treatment groups.
Pharmacological treatment
XPro1595 [13] or etanercept (Enbrel, Amgen-Wyeth,
Thousand Oaks, CA, USA) were administered intraven-
ously once, at a dose of 10 mg/kg, 30 minutes after sur-
gery. Saline was used as the vehicle. Mice subjected to
sham surgery were given an intravenous injection of saline
30 minutes after surgery. The peak concentration in serum
(Cmax) after murine intravenous dosing of XPro1595 at
10 mg/kg was 945.7 μg/ml and the terminal half-life was
19.1 hours (data not shown).
Physiological parameters
Mice were weighed at the time of pre-training, before
surgery, and one, three and five days after surgery. Rectal
temperature was measured prior to, and 30 minutes and
three hours after surgery.
Behavioral tests
Functional outcomes were evaluated one, three and five
days after pMCAO using different behavioral tests de-
signed to detect motor deficits. Prior to behavioral testing,
mice were allowed to acclimatize in the behavior room.
Grip strength test
The grip strength meter (BIO-GT-3, BIOSEB, Vitrolles,
France) was used to study neuromuscular function in
mice subjected to pMCAO and sham surgery. The peak
amount of force was recorded in five sequential trials
and the highest grip value was recorded as the score
[16]. We analyzed the grip strength in individual (left
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and five days after pMCAO. The unit of force measured
is presented as grams (g). Asymmetry between paws in
individual mice following pMCAO were calculated and
are presented as delta (Δ) grip strength measured in
grams (g). Mice that were allowed to survive for 24 hours
were tested on day one, and mice that were allowed to
survive for five days were tested on day three and five.
Horizontal rod test
In order to test motor coordination, dynamic balance
and asymmetry, mice were placed on the centre of a
horizontal rod, located 80 cm above the floor. Mice were
allowed to explore and walk the rod for three minutes.
The frequency of right and left hind limb slips was re-
corded and the total distance travelled was tracked using
the SMART video tracking software (Panlab, Barcelona,
Spain)[17].
Rotarod performance test
In order to evaluate drug-induced differences, motor co-
ordination and performance and balance [18], we per-
formed the rotarod test (LE8200, Panlab Harvard
Apparatus, Barcelona, Spain). The test comprised a pre-
training part prior to surgery (30 seconds at four rota-
tions per minute (rpm)) and a trial part consisting of
four trials (T1 to T4) 24 hours or five days after surgery.
Mice were placed on the rotarod which was set in accel-
erating mode. The speed of the rotor was accelerated
from 4 to 40 rpm over five minutes. Time spent on the
rotarod in each trial for each mouse was recorded.
Tissue processing
Fresh frozen tissue
Mice were killed by cervical dislocation, and brains and
livers were quickly removed, frozen in CO2 and stored
at −80°C until further processing. Blood samples were
collected in EDTA-coated Eppendorf tubes, spun twice
for 10 minutes at 3,000 g and 4°C, and stored at −80°C
until further processing. Brains were cut coronally in six
parallel series of 30 μm and liver samples were cut into
30 μm cryostat sections and stored at −80°C until fur-
ther processing.
Perfusion fixed tissue
Mice were deeply anesthetized with an overdose (0.15 ml)
of pentobarbital (200 mg/ml) containing lidocaine (20 mg/
ml) (Glostrup Apotek, Glostrup, Denmark) and perfused
through the left ventricle using 4% paraformaldehyde
(PFA), as previously described [19]. Brains from mice with
24 hours survival intended for immunohistochemistry for
the granulocyte marker Gr1 (see below) were cut coron-
ally in six parallel series as free-floating 60-μm thick sec-
tions and stored in a cryoprotective solution at −12°C(n = 6), or were cut coronally into 12 parallel series as
20-μm thick cryostat sections (n = 5) and stored at −20°C,
until further processing.
Flow cytometric analysis
Mice were anesthetized intraperitoneally with an over-
dose of pentobarbital containing lidocaine and perfused
through the left ventricle using phosphate-buffered sa-
line (PBS), as previously described [19]. Prior to perfu-
sion, 80 μl blood was collected from each mouse using
EDTA-coated capillaries and placed in Hanks’ balanced
salt solution (HBSS: 0.14 M NaCl, 5.4 mM KCl, 0.4 mM
MgSO4•7H2O, 0.4 mM Na2HPO4(anhydrate), 1.3 mM
CaCl22H2O, 4.2 mM NaHCO3, 0.4 mM KH2PO4,
0.5 mM MgCl26H2O, and 5 mM glucose) as previously
described [19]. Furthermore, spleen and ipsi- and
contralateral cortices were quickly removed and proc-
essed as previously described [19].
Infarct volumetric analysis
Every sixth section was stained with toluidine blue solu-
tion (TB: 0.08 M Na2HPO4•2H2O, 0.07 M citric acid, and
0.01% TB (Merck Millipore, Hellerup, Denmark)) for dir-
ect infarct volume estimation using the Cavalieri principle,
as previously described [15,16]. In addition, in order to
correct for edema, the volume of the contralateral and the
nonischemic ipsilateral cortex and the volume of injury
spanning from 1,080 μm anterior to 1,080 μm posterior of
the anterior commissure was compared using an indirect
method of infarct volume estimation [16].
Quantitative PCR
Liver and brain mRNAs were extracted using the RNeasy
Mini Kit (Qiagen, Manchester, UK)) according to the
manufacturer’s instructions. cDNA was prepared as previ-
ously described [16,20] and qPCR analysis was performed
using the following conditions: five minutes primer exten-
sion at 25°C, followed by 25 minutes reverse transcription
at 55°C and finally five minutes enzyme inactivation at
95°C, as previously described [16,20]. Samples were run
against standard curves generated from serially diluted
cDNA from liver samples obtained from mice subjected to
pMCAO. Primer sets were designed by PrimerDesign Ltd.
(Southampton, UK) and analyzed using SYBR green as pre-
viously described [20]. Primer sets were: serum amyloid A2
(SAA2) (forward: TTCATTTATTGGGGAGGCTT and re-
verse: GCCAGCTTCCTTCATGTCAG), serum amyloid
P-component (SAP) (forward: CAAGGCGGCAGAGTT
CAC and reverse: GGAGAGGATTTTTATTTGGC), Che-
mokine (C-C motif) ligand 2 (CCL2) (forward: TGAAGTT
GACCCGTAAATCTGAA and reverse: AGGCATCACA
GTCCGAGTC), interleukin (IL)-1β (forward: TGTAAT
GAAGACGGCACAC and reverse: TCTTCTTTGGGTA
TTGCTTGG), Chemokine (C-X-C motif) ligand (CXCL1)
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TGTGGCTATGACTTCGGTTTG), CXCL10 (forward:
CATCCCGAGCCAACCTTCC and reverse: CACTCA
GACCCAGCAGGAT), IL-10 (forward: AGGACTTTAA
GGGTTACT and reverse: AATGCTCCTTGATTTCTG),
iNOS (forward: GGACAGCACAGAATGTTCCAGAA
and reverse: CAAAATCTCTCCACTGCCCCAG), and
TNF (forward: GCCTCCCTCTCATCAGTTCTAT and
reverse: TTTGCTACGACGTGGGCTA). Arg1 primers
(Mm00475988_m1) were purchased from Life technologies
(Nærum, Denmark). Liver results were reported relative to
the expression of the housekeeping gene glyceraldehyde
phosphate dehydrogenase (GAPDH) [20]. All data were
normalized to the corresponding sham group, which at all
time points represented a mean value of 1. Brain TNF, IL-
1β and CD11b mRNA qPCR analyses were performed as
previously described [16].Immunohistochemistry
Immunohistochemical staining for TNF was performed
using the alkaline phosphatase-conjugated rabbit anti-
TNF antibody (Sigma-Aldrich, Brøndby, Denmark) as
described in Lambertsen et al. [21]. Visualization of
the Mac-1 antigen (CD11b; AbDSerotec, Copenhagen,
Denmark) on fresh frozen sections and the Gr1 antigen
(Ly-6G and Ly-6C, BD Biosciences, Albertslund, Denmark)
on free-floating vibratome and perfusion fixated sections
was performed with the streptavidin and horseradish per-
oxidase technique [15,22]. Substitution of the primary
antibody with serum immunoglobulin (IgG: DakoCytoma-
tion, Glostrup, Denmark) or specific isotype controls gave
no signal.Western blotting
Total protein was extracted in 1% lysis buffer (RIPA,
Merck Millipore, Hellerup, Denmark) containing a soluble
protease inhibitor cocktail (Roche Diagnostics, Hvidovre,
Denmark) according to Lambertsen et al. [16]. Protein
concentrations were estimated using the Bradford Protein
Quantification method.
Western blotting analysis for TNF (Abcam, Cambridge,
UK, 1:2,000) was performed using 20 μg protein extract
separated on bis/tris 4-12% SDS-PAGE gels (Nupage™,
Invitrogen, Tåstrup, Denmark) essentially as previously
described [16]. SeeBlue Plus2 pre-stained standard (Invi-
trogen) was used as a molecular weight marker and
0.5 ng 17 kDa murine recombinant TNF (Sigma Aldrich)
was included as a positive control. Densitometry was
performed using Image J analysis software (version 1.47,
National Institutes of Health (NIH), Bethesda, Maryland,
USA) following recommendations of the Image J devel-
opers. Analysis was performed on two independent gels
with two mice per group.Flow cytometry
Flow cytometry was performed essentially as previ-
ously described [16,19] using FACSVerse (BD Biosci-
ences) and data analyzed using the FACSuite software.
TNF+ microglia (CD11b+CD45dim), TNF+ macrophages
(CD11b+CD45highGr1−) and TNF+ granulocytes (CD11b+
CD45highGr1+) were identified as previously detailed
[16,19]. Control mice and mice allowed to survive for six
and 24 hours after pMCAO were treated intravenously
with either saline, XPro1595 or etanercept 30 minutes
after surgery.
Prior to fixation, cells were stained for live/dead cells
for 30 minutes at 4°C using a Fixable Viability Dye
eFluoro 506 (eBioscience, Hatfield, UK) diluted in PBS.
A total of 1,000,000 events were collected using forward
scatter (FSC) and side scatter (SSC) and analysis of the
live/dead gate revealed comparable numbers of dead
cells in all the samples. In addition, blood and spleen
samples were collected and analyzed for CD45, CD11b,
Gr1, and CD3 expression.
Positive staining for TNF (Biolegend, Copenhagen,
Denmark), CD11b, CD45, Gr1 and CD3 (BD Pharmingen,
Albertslund, Denmark) was determined based on fluores-
cence levels of the respective isotype controls (Biolegend
and BD Pharmingen). The mean fluorescence intensity
(MFI) was calculated as the geometric mean of each popu-
lation in the TNF, CD45 and CD11b positive gates,
respectively.
Estimation of polymorphonucleated cells within the
infarcted cortex
The number of polymorphonuclear cells/mm2 as a
measure for granulocyte infiltration six and 24 hours
after pMCAO was estimated based on nuclear morph-
ology using TB-stained sections. In practice, calibrated
high-power fields (40×) located within the infarct area,
and spanning from 1,080 μm anterior to 1,080 μm pos-
terior of the anterior commissure, were photographed
and manually counted by a blinded observer on a mini-
mum of 10 frames from each mouse.
Microvesicle analysis
In total, 100 μl of plasma was diluted 1:10 in Dulbecco’s
sterile filtered PBS (Sigma Aldrich) and centrifuged at
30,000 g for one hour to remove interfering lipoprotein
particles. The pellet was resuspended in 100 μl PBS
containing 0.1% bovine serum albumin (Sigma Aldrich)
diluted 1:10 in PBS immediately prior to analysis. Micro-
vesicle size and concentration were determined by
Nanoparticle Tracking Analysis (NTA) using a NS500
analyser equipped with a 488 nm laser and NTA soft-
ware (Nanosight Ltd, Espoo, Finland) as previously de-
scribed [23]. Analysis settings were standardized using
100 nm colloidal silica microspheres (100, 150, 300 and
Figure 1 Systemic anti-TNF therapy does not affect infarct
volume after focal cerebral ischemia. (A) Toluidine blue staining
of brain sections from mice treated with either saline, XPro1595 or
etanercept and allowed to survive for either six hours, 24 hours or
five days. Scale bar: 1 mm. (B) Direct infarct volume measurements
showed no difference in infarct volumes between saline-, XPro1595-
and etanercept-treated mice at either six hours ( eight to 15 per
group), 24 hours (15 per group) or five days (14 to 17 per group)
(one-way ANOVA). A significant drop in infarct size was observed in
all three groups five days after pMCAO, compared to six and
24 hours (*P <0.05, **P <0.01). ANOVA, analysis of variance; d, days;
h, hours; IF, infarct; pMCAO, permanent middle cerebral artery
occlusion; Str, striatum.
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data were used to verify size measurements and calibrate
concentration measurements. Five 30-second videos
were made for each sample. The sample was advanced
with a five-second delay between each recording using
the script control facility. The videos were analyzed in
batch process mode using automatic blur and minimum
expected particle size with an automatic detection
threshold level 10, after visually checking that the five
size profiles on the screen were in concordance.
Data analysis
Quantitative data are presented as means ± standard
error of mean (SEM). Weight and temperature analyses
were performed using two-way repeated measures (RM)
analysis of variance (ANOVA). Infarct volumetric ana-
lysis, qPCR, flow cytometry, grip strength and microvesi-
cle analyses were performed using one-way ANOVA.
Grip strength asymmetry and horizontal rod analyses
were performed using paired t-tests. Pearson correlation
analysis was used to analyze correlations between liver
chemokines and between microvesicle counts and infarct
volumes. All statistical analyses were followed by the ap-
propriate post-hoc test and performed using Prism 6
software for Macintosh (GraphPad software, La Jolla,
CA, USA) and considered significant at P ≤0.05.
Results
Systemically injected anti-TNF therapy does not affect
infarct size after permanent focal cerebral ischemia
Focal cerebral ischemia produced a cortical infarct,
which was visible in TB-stained sections at six hours,
24 hours and five days after pMCAO (Figure 1A). Com-
parison of mean infarct volumes showed that anti-TNF
therapy targeting either solTNF using XPro1595, or both
solTNF and tmTNF using etanercept, did not affect in-
farct size at six hours (P = 0.79), 24 hours (P = 0.76) or
five days (P = 0.92) after pMCAO (Figure 1B). In line
with previous studies [24], we found that in all three
groups infarct size had decreased at five days, most
likely as a result of edema resolution and resorption of
infarcted tissue. Indirect infarct volumetric analysis also
revealed no differences in edema formation between the
different groups (data not shown).
XPro1595 and etanercept improve functional outcome
after focal cerebral ischemia
In order to distinguish between solTNF- and tmTNF-
mediated effects on functional recovery, we evaluated
behavior and motor function in mice subjected to
pMCAO and treated with either XPro1595 or etaner-
cept. To identify and validate significant behavioral im-
provements, we also included groups of mice subject to
sham surgery.We detected a post-surgical weakness of both the left
(L) and right (R) front paws in saline- and XPro1595-
treated mice 3 and 5 days after pMCAO compared to
normal baseline grip strength (Figure 2A). Etanercept-
treated mice showed no difference on the left paw,
Figure 2 Anti-TNF therapy improves functional outcomes after focal cerebral ischemia. (A) Neuromuscular function presented as grip strength in
grams (g), showing post-surgical weakness in both left and right front paws in saline- and XPro1595-treated mice three and five days after pMCAO compared
to baseline grip strength. Etanercept-treated mice showed no loss of grip strength on the left paw, but a significant reduction in grip strength three and five
days after pMCAO. BL, baseline. (P < 0.05, ***P < 0.001, ****P < 0.0001 (B) Grip strength analysis at 24 hours after pMCAO showed that asymmetry (Δ grip
strength) was evident in saline-treated mice (***P <0.001, paired t-test) and, to a lesser extent, in XPro1595-treated mice (*P <0.05), but no asymmetry was
observed in etanercept-treated or sham mice (six to 14 per group)(left graph). Grip strength analysis at five days showed that asymmetry was still present in
saline-treated mice (*P <0.05) but not in sham, XPro1595- and etanercept-treated mice (13 to 17 per group)(right graph). (C) The horizontal rod test showed
that only saline-treated mice displayed asymmetry both 24 hours (left graph) and five days (right graph) after pMCAO as saline-treated mice displayed
significantly more slips on the right hind limb compared to the left limb after pMCAO (**P <0.01, paired t-test), whereas sham, XPro1595- and etanercept-
treated mice did not display any asymmetry (six to 17 per group). (D) Assessment of motor function using the rotarod test showed that saline-treated mice
subjected to focal cerebral ischemia did not display normal learning skills at 24 hours (left graph) and five days (right graph), whereas both XPro1595- and
etanercept-treated mice displayed normal learning skills (T1 to T4) both at 24 hours and five days, comparable to sham mice (*P < 0.05, **P < 0.01, one-way
ANOVA, five to six per group. g, grams; L, left; pMCAO, permanent middle cerebral artery occlusion; R, right; T, trial; sec, seconds.
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(Figure 2A). XPro1595- and etanercept-treated mice per-
formed significantly better on day 3 compared to saline-
treated mice (Figure 2A). Further, grip strength analysis
showed significant pMCAO-induced front paw asymmetry
in saline-treated mice 24 h and 5d after pMCAO as com-
pared to sham mice and pre-treatment baseline grip
strengths (represented by delta (Δ) values) (Figure 2B).
Minor asymmetry was observed in XPro1595-treated mice
at 24 h, but not at 5d (Figure 2B). No asymmetry was ob-
served in etanercept-treated mice. The increase in Δ grip
strength observed on the left paws in all mice 24 h after
pMCAO is likely a result of an increased ”flight-or-fight”
response observed at this early time point after surgery
[16]. All together, the grip strength data indicate that anti-
TNF therapy ameliorates neuromuscular asymmetry nor-
mally caused by pMCAO.
The horizontal rod test supported the findings from the
grip strength test in saline-treated mice, but showed no
asymmetry of the hindlimbs in XPro1595- and etanercept-
treated mice 24 h and 5d after pMCAO (Figure 2C). We
found no difference in distance travelled (cm) (P = 0.52,
data not shown) or speed (cm/sec) (P = 0.82, data not
shown) between sham and saline-treated pMCAO mice.
Also, distance travelled and speed in anti-TNF-treated
mice were comparable to sham and saline-treated mice.
The rotarod test showed significantly altered motor learn-
ing skills in saline-treated mice 24 h and 5d after pMCAO
compared to sham mice, a change which was not observed
in XPro1595- and etanercept-treated mice (Figure 2D).
These data suggest that XPro1595 and etanercept im-
proved motor learning skills after focal cerebral ischemia.
Physiological parameters
To exclude the possibility that the improved behavioral
effects were merely a result of reduced core temperature,
which is neuroprotective [25], we monitored rectal body
temperature during and after anti-TNF therapy (Table 1).Table 1 Assessment of physiological parameters in saline-, XP
ischemia
Time point Sham Saline
Weight (Δg)
D0 0.69 ± 0.15 0.48
D1 0.19 ± 0.17 0.16
D3 ****-0.61 ± 0.20 ****-0.
D5 *0.14 ± 0.27 **0.11
Temperature (°C)
BL 32.69 ± 0.49 32.21
30 min after pMCAO ***27.28 ± 0.22 ***27.3
3 h after pMCAO ***27.15 ± 0.32 ***26.8
BL, baseline. Data are presented as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, *Results showed that all groups experienced a significant
anesthesia-induced drop in rectal temperature 30 min
and 3 h after surgery (P < 0.001), an outcome induced by
the immobilization of the mice, however there were no
differences between treatment groups. Also, no differ-
ences were observed in changes in body weights (Δ
weight loss (g)) at any time point between treatment
groups (Table 1). However, all 4 groups of mice dis-
played a significant drop in weight from baseline to day
3 (P < 0.0001 for all groups) and day 5 (P < 0.01 for sa-
line, XPro1595 and etanercept); however the weight
drop at day 5 was less in the sham group (P < 0.05).
Anti-TNF therapy affects microglial activation
We have previously shown that TNF is preferentially
produced by microglia (CD11b+CD45dim cells) and mac-
rophages (CD11b+CD45highGr1− cells) after pMCAO
[16,19]. Consequently, we sought to examine whether
anti-TNF therapy altered microglial and/or leukocyte re-
sponses in the brain.
In order to evaluate the effect of XPro1595 and etaner-
cept on microglial and leukocyte reactions, we investi-
gated the number of CD11b+CD45dim microglia and
CD11b+CD45high leukocytes in the different treatment
groups after pMCAO (Figure 3A, B). The total number
of CD11b+CD45dim microglia was found to be signifi-
cantly increased in all treatment groups at six and
24 hours after pMCAO, compared to non-lesioned con-
trol mice. Interestingly, when the CD11b+CD45dim
microglial population was evaluated in mice treated with
either XPro1595 or etanercept and allowed to survive
for 24-hours, the estimated number of CD11b+CD45dim
microglia in the lesioned cortex had increased in
etanercept-treated mice, though not quite significant,
and significantly in XPro1595-treated mice as compared
to saline-treated mice (Figure 3B, upper left graph). Esti-
mation of the number of infiltrating CD11b+CD45high
leukocytes showed a significant increase in all treatmentro1595- and etanercept-treated mice after focal cerebral
XPro1595 Etanercept
± 0.16 0.41 ± 0.14 0.45 ± 0.17
± 0.20 0.12 ± 0.24 0.11 ± 0.21
79 ± 0.22 ****-0.89 ± 0.15 ****-0.81 ± 0.14
± 0.18 **-0.12 ± 0.22 **-0.14 ± 0.29
± 0.38 31.95 ± 0.32 32.41 ± 0.35
7 ± 0.22 ***27.52 ± 0.15 ***27.41 ± 0.21
9 ± 0.27 ***26.51 ± 0.30 ***26.59 ± 0.28
***P < 0.0001 (two-way repeated measures ANOVA).
Figure 3 Analysis of brain microglial/leukocyte responses after anti-TNF therapy. (A) Gating strategy: FSC/SSC was used to define
leukocytes, monocytes and granulocytes. Singlet cells were identified using FSC-A/FSC-H, and only live cells were included. Dot plots showing
CD45highGr1+ granulocytes,, CD45dimCD11b+ microglia, and CD45highCD11b+Gr1- macrophages (B) Microglial numbers were increased at six and
24 hours in all groups compared to the respective non-lesioned mice. Furthermore, the number of microglia was significantly increased in
XPro1595-treated mice compared to saline-treated mice at 24 hours. MFI for CD45 in microglia was significantly increased at 24 hours in
XPro1595- and etanercept-treated mice compared to saline-treated mice. Analysis of CD11b+CD45high leukocytes showed an increase in the
number of infiltrating leukocytes in all groups at 24 hours compared to non-lesioned mice. No change in MFI for CD45 in leukocytes was
observed (four to six per group). (C) CD11b-immunostained sections six hours, 24 hours and five days after pMCAO (shown for saline-treated
mice). Scale bar: 100 μm. cc: corpus callosum, IF: infarct. (D) Anti-TNF therapy did not affect brain CD11b and iNOS mRNA levels. Brain IL-1β mRNA
levels were found increase at 24 hours in etanercept-treated mice, compared to six hours and five days and to saline- and XPro1595-treated mice.
Arg1 mRNA levels were found to increase in saline-treated mice at 24 hours compared to six hours and five days and in XPro1595-treated mice at
24 hours compared to five days. IL-10 mRNA levels were found to decrease in XPro1595-treated mice 24 hours and five days compared to six
hours (one-way ANOVA, four to six per group). (*P <0.05, **P <001). Arg1, arginase 1; ANOVA, analysis of variance; FSC, forward scatter; IL,
interleukin; iNOS, inducible nitric oxide synthase; MFI, mean fluorescent intensity; pMCAO, permanent middle cerebral artery occlusion; SSC, side
scatter; TNF, tumor necrosis factor; qPCR, quantitative polymerase chain reaction.
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mice, but otherwise revealed no difference among treat-
ment groups (Figure 3B, upper right graph). The total
number of CD11b+CD45dim microglia was also found
to increase at 24 hours in the contralateral cortex
(P <0.01), but no changes were found between treatment
groups (P >0.05, data not shown). The total number ofCD11b+CD45high leukocytes did not change in the
contralateral cortex after pMCAO in any of the treat-
ment groups (P >0.05, data not shown).
Since microglia and leukocytes become activated by
pMCAO [19], we investigated whether the cellular level
of CD45, a protein known to be involved in activation of
hematopoietic cells, was affected at 24 hours. MFI
Clausen et al. Journal of Neuroinflammation 2014, 11:203 Page 9 of 17
http://www.jneuroinflammation.com/content/11/1/203analysis showed a significant increase in CD45 by micro-
glia in XPro1595- and etanercept-treated mice as com-
pared to saline-treated mice (Figure 3B, lower left
graph); however, CD45 expression was comparable on
leukocytes 24 hours after pMCAO (Figure 3B, lower
right graph). Furthermore, since TNF has been directly
shown to regulate CD11b expression in mouse micro-
glial cells [26], we also investigated whether CD11b ex-
pression was affected by TNF treatment 24 hours after
pMCAO. However, no differences were observed in the
MFI for CD11b by microglia or leukocytes (P = 0.73 and
P = 0.79, respectively, data not shown). MFI values for
CD45 and CD11b did not change in the contralateral
cortex for microglia (P = 0.94 and P = 0.17, respectively,
data not shown) or leukocytes (P = 0.07 and P = 0.33, re-
spectively, data not shown). These results suggest that
microglial activation is increased in the ipsilateral hemi-
sphere in anti-TNF-treated mice. Using immunohisto-
chemistry, we found CD11b+ cells to be distributed
similarly in all three treatment groups (Figure 3C, shown
for saline only).
Based on the increased number of CD11b+CD45dim
microglia 24 hours after pMCAO in anti-TNF-treated
mice, we next investigated whether anti-TNF therapy af-
fected the phenotype of microglial activation after
pMCAO. Using qPCR, we found no differences in
CD11b mRNA or iNOS mRNA levels between saline-
and anti-TNF-treated groups (Figure 3D). In contrast,
IL-1β mRNA levels were found to be significantly in-
creased in etanercept-treated mice compared to saline-
treated mice 24 hours after pMCAO, suggesting that
blocking both solTNF and tmTNF increases mRNA
levels of this pro-inflammatory cytokine. Even though
Arg1 mRNA levels were found to change significantly
over time in saline- and XPro1595-treated mice, there
were no difference between treatment groups at the dif-
ferent time points investigated. The same was true for
IL-10 mRNA levels, which were found to change signifi-
cantly over time in saline-treated mice, but no differ-
ences were observed between treatment groups. These
findings suggest that etanercept treatment may induce
mRNA changes associated with an M1 phenotype at
24 hours, whereas no changes were observed between
treatment groups in the M2 phenotype.
Changes in TNF levels in mice treated with anti-TNF
therapy
TNF mRNA+ cells were observed within the infarct and
peri-infarct in all groups after pMCAO (Figure 4A,
shown for saline only). Cells were most numerous at
24 hours, with very few cells observed at five days. These
findings were confirmed by qPCR, showing a transient
increase in TNF mRNA at 24 hours (Figure 4A). As part
of the acute phase response (APR) to brain injury, TNFmRNA+ cells were also found in the liver primarily six
hours after pMCAO, as supported by qPCR analysis
(Figure 4B). By 24 hours, there was a significant reduc-
tion in TNF mRNA transcription in the liver in saline-
and XPro1595-treated mice, consistent with findings of
very few TNF mRNA+ cells. To study whether anti-TNF
therapy was capable of reducing TNF levels in the brain
within the therapeutic window, we first performed im-
munohistochemistry on tissue from mice that had sur-
vived six hours, 24 hours and five days after pMCAO
(Figure 4C). At six hours, TNF+ microglial and leukocyte-
like cells were located within the infarct and in the peri-
infarct in saline-treated mice six hours after pMCAO
(inserts in Figure 4C), and rarely observed in anti-TNF-
treated mice. At 24 hours and five days, cells were found
to be located in the infarct and in the peri-infarct (low
magnifications in Figure 4C, shown for 24 hours only)
in all treatment groups. The cells were found to have
microglial- and leukocyte-like morphology (high magnifi-
cations in Figure 4C). In order to support the findings of
reduced TNF+ cells at six hours in anti-TNF-treated mice,
we performed Western blotting for TNF on brain tissue
from mice allowed to survive for six- and 24-hours
(Figure 4D). We found reduced TNF levels at six hours in
XPro1595-treated mice, and even more so in etanercept-
treated mice, as compared to saline-treated mice, suggest-
ing that both types of anti-TNF therapies were capable of
reducing TNF availability within six hours after pMCAO.
At 24 hours, comparable TNF levels were found by
Western blotting, supporting the immunohistochemis-
try data.
Using flow cytometry, we further investigated changes
in the number of TNF producing microglia (TNF+CD11b+
CD45dim cells), macrophages (TNF+CD11b+CD45highGr1−
cells) and granulocytes (TNF+CD11b+CD45highGr1+ cells)
six and 24 hours after pMCAO compared to non-lesioned
control mice (Figure 4E). We found a tendency towards a
reduced number of TNF+CD11b+CD45dim microglia in
XPro1595-treated non-lesioned control mice and mice
allowed to survive for six hours, however this was not sig-
nificant (Figure 4E, upper panel). At 24 hours, the number
of TNF+CD11b+CD45dim microglia had increased signifi-
cantly in all treatment groups compared to non-lesioned
control mice, with no differences between treatment
groups (Figure 4E). TNF+ macrophages (TNF+CD11b+
CD45highGr1− cells) and TNF+ granulocytes (TNF+CD11b+
CD45highGr1+ cells) (Figure 4E, lower panel) were not de-
tected by flow cytometry in the ischemic infarct until
24 hours after pMCAO and at this time point there were
no differences between treatment groups. Note that at
24 hours, the total number of TNF-producing leukocytes
was significantly lower than the number of TNF-producing
microglia (Figure 4E, please compare upper graph with
lower graph).
Figure 4 Liver and brain TNF expression following anti-TNF therapy. (A) TNF mRNA+ cells six hours, 24 hours and five days after pMCAO
(shown for saline-treated mice). Scale bar: 30 μm. TNF mRNA levels increased transiently at 24 hours (four to six per group). (B) A few TNF mRNA+
cells were located in the liver preferentially at six hours (shown for saline-treated mouse), but also to some extent in etanercept-treated mice at
24 hours. Scale bar: 30 μm. Liver TNF mRNA levels were decreased in saline-treated mice at 24 hours compared to six hours and in XPro1595-
treated mice at 24 hours compared to six hours and five days (*P <0.05, **P <0.01, three to six per group). (C) TNF stained sections from mice that
had survived six hours (inserts), 24 hours and five days. At 24 hours and five days TNF protein expression was localized to the infarct and
peri-infarct and cells displayed microglial and leukocyte morphology. Scale bars = 200 μm (low magnifications) and 20 μm (high magnifications).
(D) Western blots for TNF levels after pMCAO demonstrating reduced TNF levels at six hours in XPro1595- (27.9% ± 3.3%) and etanercept-treated
(16.2% ± 2.3%) mice compared to saline-treated mice (100% ± 1.3%) (***P <0.001, one-way ANOVA, followed by Bonferroni post-hoc test). At
24 hours, TNF protein levels were comparable in saline- (100% ± 50.3%), XPro1595- (102.7% ± 3.4%) and etanercept-treated (93.2% ± 20.4%) mice.
(E) Flow cytometry profiles gated on CD11b+CD45+ cells showing primarily TNF+ microglia at 24 hours after pMCAO. Only few TNF+ macrophages
and TNF+ granulocytes were present at 24 hours (four to six per group, **P <0.01; ****P <0.0001). ANOVA, analysis of variance; d, days; FMO,
fluorescence minus one; h, hours; pMCAO, permanent middle cerebral artery occlusion; rTNF, recombinant TNF; TNF, tumor necrosis factor; qPCR,
quantitative polymerase chain reaction.
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infarct 24 hours after focal cerebral ischemia
As TNF facilitates granulocyte infiltration into the CNS
[27], we counted the number of granulocytes in the infarct
six and 24 hours after pMCAO (Figure 5). Based on their
characteristic nuclear morphology (between two and five
lobes), which was further verified using an anti-Gr1 anti-
body (Figure 5A, left), we observed comparable numbers/
mm2 of granulocytes six hours after pMCAO, but increased
numbers/mm2 in saline-treated mice 24 hours after
pMCAO compared to anti-TNF-treated mice (Figure 5B).
Using flow cytometry, we found a significant increase in
the number of CD11b+CD45highGr1+ granulocytes at
24 hours compared to non-lesioned control mice, however
the number was comparable in the whole ipsilateral cor-
tex in all three groups at all time points investigated
(Figure 5C).Figure 5 The effect of anti-TNF therapy on the number of granulocyt
brain sections from saline-, XPro1595-, and etanercept-treated mice allowed
infiltration of polymorphonucleated cells into the ischemic infarct. Co-local
granulocyte (Gr1) marker was verified using immunohistochemistry in salin
and right 10 μm. (B) Estimation of the number of infiltrating polymorphon
increased number of cells in saline-treated mice (58.6 ± 14.1 granulocytes/m
mm2) 24 hours after ischemia (*P <0.05, one-way ANOVA, followed by Bon
analysis of the number of infiltrating CD11b+CD45highGr1+ cells in the ipsila
after pMCAO showed a significant increase in the total number of infiltratin
24 hours compared to non-lesioned control mice. No difference between t
of variance; h, hours; pMCAO, permanent middle cerebral artery occlusion;Anti-TNF therapy affects the liver acute phase response
after focal cerebral ischemia
Since anti-TNF therapy improved functional outcome
without affecting infarct size, and since suppression of the
APR has previously been shown to correlate with im-
provements in behavior in motivational tests [28], we
analyzed the peripheral APR. Hepatic expression of che-
mokine ligand CXCL10, involved in monocyte and macro-
phage and natural killer (NK) cell infiltration, was
significantly altered by etanercept at 24 hours compared
to six hours and five days after pMCAO (Figure 6A).
CXCL10 mRNA levels in saline- and XPro1595-treated
mice remained relatively constant over time, whereas we
observed a significant increase in etanercept-treated mice.
Since we observed no effect of blocking only solTNF on
CXCL10 mRNA, these data suggest a close interplay be-
tween tmTNF and CXCL10 mRNA regulation in the liver.es in the infarct. (A) Representative photomicrographs of TB-stained
to survive for 24 hours after focal cerebral ischemia, demonstrating
ization of polymorphonucleated cells in TB-stained sections with a
e-treated mice allowed to survive for 24 hours. Scale bars: left 30 μm
ucleated cells per mm2 within the infarct showed a significantly
m2) compared to XPro1595-treated mice (17.4 ± 3.0 granulocytes/
ferroni post-hoc test; four to eight per group). (C) Flow cytometry
teral neocortex of non-lesioned control mice and mice six and 24 hours
g granulocytes in saline-, XPro1595- and etanercept-treated mice at
reatment groups was observed (four to six per group). ANOVA, analysis
TB, toluidine blue; TNF, tumor necrosis factor.
Figure 6 The effect of anti-TNF on the APR after focal cerebral ischemia. (A) Changes in liver CXCL10, CXCL1, CCL2, IL-1β, SAA2 and SAP
mRNA levels after pMCAO (*P <0.05, **P <0.01, one-way ANOVA followed by Bonferroni post-hoc test, three to six per group). (B) Flow cytometry
analysis of spleen samples six and 24 hours after pMCAO show a decrease in numbers of T-cells (CD45+CD3+) in XPro1595- and etanercept-
treated mice 24 hours after pMCAO compared to non-lesioned mice. At 24 hours, the number of T-cells were decreased in etanercept-treated
mice compared to saline-treated mice. The number of monocytes (CD11b+CD45highGr1−) was found to increase in XPro1595-treated mice at six
hours and decrease at 24 hours, compared to non-lesioned mice. The number of granulocytes (CD11b+CD45highGr1+) was found to increase at
six hours in all groups compared to non-lesioned mice, and to decrease at 24 hours in saline- and XPro1595-treated mice. (C) Flow cytometry
analysis of blood samples showed that the number of T-cells increased at six hours in saline-treated, but not in XPro1595- and etanercept-treated
mice, compared to non-lesioned mice. The total number of T-cells was increased in saline-treated mice compared to XPro1595- and etanercept-
treated mice at six hours. At 24 hours, the total number of T-cells was decreased in all treatment groups. No change was observed at any time
point in blood monocytes. The number of granulocytes was found to increase in blood in saline-treated mice at six hours compared to
non-lesioned mice, but also compared to XPro1595- and etanercept-treated mice with six hours survival (*P <0.05, four to six per group). ANOVA,
analysis of variance; APR, acute phase response; CCL, chemokine (C-C motif) ligand; CXCL, chemokine (C-X-C motif) ligand; IL, interleukin; pMCAO,
permanent middle cerebral artery occlusion; SAA2, serum amyloid A2; SAP, serum amyloid P; TNF, tumor necrosis factor.
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CXCL1, primarily involved in granulocyte infiltration, were
significantly lower in etanercept-treated mice compared to
XPro1595-treated mice (Figure 6A). At five days, weobserved an overall drop in CXCL1 mRNA in saline- and
XPro1595-treated mice, but not in etanercept-treated
mice. These data suggest that liver CXCL1 mRNA expres-
sion is affected differently by tmTNF and solTNF after
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to as monocyte chemotactic protein, mRNA levels were
only affected in XPro1595-treated mice, which displayed a
transient increase 24 hours after pMCAO compared to
both six hours and five days (Figure 6A), suggesting that
solTNF plays a role in recruitment of monocytes into the
liver. The mRNA levels of IL-1β, which is known to be in-
volved in neurotoxicity after focal cerebral ischemia [1],
were significantly increased 24 hours after pMCAO in
anti-TNF-treated mice (Figure 6A), but there were no dif-
ferences between saline-, XPro1595- and etanercept-
treated mice.
Two late-phase APR proteins, serum amyloid A2
(SAA2) and serum amyloid P-component (SAP), both of
which are known to be regulated by proinflammatory cy-
tokines such as TNF and IL-1β, were also investigated
(Figure 6A). Anti-TNF therapy following pMCAO did
not influence liver SAA2 or SAP mRNA levels. Liver
SAP mRNA levels did not differ at any time point after
pMCAO. Correlation analyses of liver chemokine
expression after pMCAO are presented in Additional
file 1: Table S1.
Flow cytometric analyses of spleen leukocyte popula-
tions (Figure 6B) showed that the number of CD45+CD3+
T-cells in the spleen was significantly decreased in
XPro1595- and etanercept-treated mice 24 hours after
pMCAO compared to non-lesioned control mice. Further-
more, the number of T-cells was significantly decreased in
etanercept-treated mice compared to saline-treated mice
at 24 hours (Figure 6B). These findings can possibly be ex-
plained by reports of increased caspase-induced apoptosis
induction of T-cells in the spleen following treatment with
anti-TNF therapies, such as infliximab [29]. In the spleen
we also found significant changes in the total number of
spleen CD11b+CD45highGr1− monocytes in XPro1595-
treated mice, with a significant increase at six hours and a
significant decrease at 24 hours compared to non-lesioned
XPro1595-treated control mice (Figure 6B). No changes
were observed in saline- or etanercept-treated mice and
no significant difference was observed between groups.
Also, the total number of spleen CD11b+CD45highGr1+
granulocytes changed significantly over time compared to
non-lesioned control mice. There was as significant in-
crease in all groups of mice at six hours and a significant
decrease in saline- and XPro1595-treated mice at 24 hours
(Figure 6B). Flow cytometric analyses of blood leukocyte
populations (Figure 6C) showed a significant increase in
circulating T-cells in saline-treated mice at six hours and a
significant decrease in all treatment groups at 24 hours
compared to non-lesioned control mice. At six hours, the
total number of circulating T-cells was also significantly
increased in saline-treated mice compared to both
XPro1595- and etanercept-treated mice. No changes were
observed in the total number of circulating bloodmonocytes at any time point investigated, or between
treatment groups. In the blood, the total number of circu-
lating granulocytes significantly increased in saline-treated
mice compared to both non-lesioned control mice and
compared to XPro1595- and etanercept-treated mice
allowed to survive for six hours. These results demon-
strated that anti-TNF therapy decreased the total number
of circulating T-cells and granulocytes early (six hours)
after pMCAO.
Anti-TNF therapy impacts microvesicle size and number
after focal cerebral ischemia
As microvesicle number and infarct size have been
shown to correlate and possibly be an indicator of in-
flammation, we analyzed microvesicle number and size
after pMCAO. Comparisons showed similar numbers
in saline- (2.7 ± 0.5 × 1010/ml) and anti-TNF-treated
control mice (XPro1595: 3.3 ± 0.2 × 1010/ml and etaner-
cept 3.2 ± 0.8 × 1010/ml). By six hours, we found signifi-
cantly more microvesicles in XPro1595-treated mice
compared to saline-treated mice (Figure 7A), an effect
which was observed in both XPro1595- and etanercept-
treated mice five days after pMCAO. When investigat-
ing temporal changes, we observed significant increases
in microvesicle numbers in all groups five days after
pMCAO compared to survival for six hours.
Overall, the mean diameter of microvesicles changed
over time, but not within treatment groups. There was a
general increase in the mean size at six hours compared
to controls (saline: 170.8 ± 5.3 nm; XPro1595: 170.0 ±
6.5 nm; and etanercept: 190.0 ± 5.0 nm; P <0.05) and five
days after pMCAO, compared to 24 hours after pMCAO
(Figure 7B). The difference in microvesicle size over time
most likely reflects differences in origin. Interestingly, at
24 hours we observed a small yet significant correlation
between microvesicle numbers and infarct volume in
saline-treated mice, but not in anti-TNF-treated mice
(Figure 7C). This correlation was not observed at any
other time point.
Discussion
In the present study, we found that in a mouse model of
focal cerebral ischemia, two different TNF inhibitors im-
proved functional outcome, modified the hepatic APR,
changed microglial CD45 expression in the neocortex and
affected microvesicle numbers in the serum, without af-
fecting lesion volume. Selective inhibition of solTNF using
XPro1595 had comparable effects with non-selective in-
hibition of both solTNF and tmTNF using etanercept,
suggesting that solTNF plays an important role in the ob-
served effects.
The finding that anti-TNF therapy did not have an effect
on lesion volume, but improved behavioral outcome in the
present study, has previously been shown in an animal
Figure 7 The effect of anti-TNF therapy on microvesicle counts and size. (A) Estimations of the total numbers of microvesicles after focal
cerebral ischemia showing altered counts with anti-TNF therapy. (B) Estimation of the mean diameter of microvesicles after focal cerebral ischemia.
(C) Correlation analysis of the total count of microvesicles and the infarct size at six hours (top), 24 hours (middle) and five days (bottom) after focal
cerebral ischemia showing a significant correlation in saline-treated mice at 24 hours. Area fill for 24 hours is shown in grey (*P <0.05; **P <0.01;
***P <0.001, ****P <0.0001, Pearson r correlation analysis and one-way ANOVA, followed by Bonferroni post-hoc test; three to 24 per group). mm,
millimeter; nm, nanometer; TNF, tumor necrosis factor.
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[30]. Also, in a model of transient focal cerebral ischemia in
mice, Sumbria et al. [31] showed that systemic injection of
etanercept had no effect on lesion volume. We also recently
showed that anti-TNF therapy had no effect on lesion size
after spinal cord injury when administered systemically,
however when anti-TNF therapies were administered epi-
durally for three consecutive days using mini-osmotic
pumps, we observed both a reduction in lesion size and an
improvement in functional outcome in XPro1595-treated
mice, but not in etanercept-treated mice [12]. These
findings suggest that anti-TNF therapies have to be ad-
ministered directly to the lesioned CNS in order to affect
lesion size. Recent findings that systemically administered
XPro1595 (10 mg/kg) does indeed cross the blood-brain
barrier (BBB) [32] and the findings in the present study that
CNS TNF levels are reduced six hours after pMCAO in
anti-TNF-treated mice suggest that both etanercept and
XPro1595 may have crossed the BBB, however this could
also be the result of endothelial dysfunction rather than
transport across the BBB [33]. Future studies using mini-osmotic pumps following experimental stroke are needed
in order to clarify whether XPro1595 can also reduce lesion
size after experimental stroke.
One-way etanercept has been shown to improve be-
havior is through anti-nociceptive effects. Boettger et al.
showed improved locomotor and pain-related behavior
after etanercept treatment in a rat model of chronic
antigen-induced arthritis, even with no resolution in
joint swelling and inflammation, and suggested that re-
duction of the effect of peripheral TNF on pain fibers
contributed to pain relief [34]. This could also be the
case in the present study, however, this will require fur-
ther investigation. The suppression of granulocyte re-
cruitment to experimental stroke lesions has previously
been shown to reduce infarct volume and reduce cell
death, but this has usually been linked to associated re-
ductions in infarct volume [35]. A reduction of granulo-
cyte infiltration into the lesioned brain in animals
treated with etanercept has been suggested to be medi-
ated via etanercept’s effect on the APR in the liver [28].
In the present study, we found that anti-TNF therapy
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mRNA expression of chemokines associated with gran-
ulocyte recruitment, such as CXCL10 and CXCL1.
Systemic injections of etanercept have also previously
been found to attenuate traumatic brain injury by ameli-
orating neurological and motor dysfunction and by ini-
tially reducing brain TNF protein levels [36,37]. Despite
unaltered brain TNF mRNA levels and comparable
numbers of TNF+ microglia and leukocytes at 24 hours
in the different experimental groups, we found that brain
TNF protein levels were decreased six hours after
pMCAO in mice treated with anti-TNF therapy, which
is in line with the mechanism of action of both
XPro1595 and etanercept neutralizing TNF at the pro-
tein level. In the present study, TNF+ cells were located
in the infarct and peri-infarct at six hours in all three ex-
perimental groups, but to a much lesser extent in
XPro1595- and etanercept-treated mice than in saline-
treated mice. Furthermore, the morphology of TNF+
cells in XPro1595- and etanercept-treated mice were
more glial-like, whereas the morphology in saline-
treated mice were mixed glial-like and macrophage-like,
suggesting that the reduced levels of TNF in the anti-
TNF-treated mice could be due to a peripheral reduc-
tion in TNF produced by infiltrating macrophages.
Etanercept has been suggested to ameliorate microglial
activation [38], however, in the present study, we found no
effect of anti-TNF therapy on CD11b expression, whereas
microglial, but not macrophage, CD45 expression was
increased in the ipsilateral hemisphere 24 hours after anti-
TNF treatment. This, combined with the increased num-
ber of CD11b+CD45dim microglia 24 hours after pMCAO,
suggests that anti-TNF therapy either increases microglial
proliferation in the brain or increases the surface expres-
sion of the CD45 marker on microglia as a response to
treatment in the ischemic brain. Previous studies have
shown that increased CD45 expression is involved in
‘microglial alertness’ and activation following injury to the
CNS, and that an increase in this surface protein likely re-
flects a response to ongoing neuroinflammation [39], sug-
gesting that anti-TNF treatment may induce increased
activation of microglia.
Microvesicles have been described as important media-
tors of intercellular communication and are emerging as
potential biomarkers of tissue damage. Interestingly,
microvesicles have been found to propagate inflammatory
signals [40], and the subtypes of endothelial microvesicles
from stroke patients have been shown to correlate with le-
sion volume and functional outcome [41]. Importantly, in
the present study, microvesicle numbers in saline-treated
mice 24 hours after pMCAO were found to correlate sig-
nificantly with infarct volume, which was not the case in
either etanercept- or XPro1595-treated mice, suggesting
an altered response due to anti-TNF therapy. In line withthis, we observed increased numbers of microvesicles in
anti-TNF-treated mice five days after pMCAO. The
microvesicles showed characteristics of shed microvesicles
due their mean diameter of 200 nm [42]. As the increase
in microvesicle number does not appear to correlate to
the infarct volume in anti-TNF-treated groups, we specu-
late that the vesicles contribute to an altered inflammatory
response in the brain, as microvesicles represent an im-
portant means of intercellular communication between
cells, serving as transfer vehicles for proteins, lipids, RNA
and microRNA [42]. In addition, microvesicles are known
to exchange information with endothelium, thereby ac-
tively regulating vascular function or participating in vas-
cular rearrangement [43]. However, their precise functions
are still not fully understood.
Based on the data presented here, we suggest that
XPro1595 and etanercept improve functional outcome in
mice subjected to focal cerebral ischemia by altering the
peripheral immune response leading to decreased infiltra-
tion of granulocytes into the infarct, potential altered
microglial alertness and, most likely, an improvement in
motivational state. The finding that XPro1595 was just as
efficient as etanercept in improving functional outcome
and altering the APR suggests that solTNF (and not
tmTNF) is principally involved in peripheral inflammation
after stroke. Finally, previous studies have indicated a dir-
ect correlation between TNF and blood pressure in hyper-
tensive humans [44] and have reported a decrease in
blood pressure in an experimental model of systemic
lupus erythematosis, a chronic inflammatory disorder with
prevalent hypertension, following etanercept administra-
tion weekly for a duration of four weeks [45]. In the
present study, we only administered etanercept once,
30 minutes after induction of experimental stroke, which
did not appear to affect either the mortality or health sta-
tus of the mice, however, whether etanercept did indeed
reduce blood pressure in the present study remains to be
elucidated in future studies.
All together, these findings may have important impli-
cations for future treatments of solTNF-mediated dis-
eases, where anti-TNF therapy targeting both solTNF
and tmTNF can be substituted with drugs only targeting
solTNF, potentially resulting in less severe side effects
for the patient, including demyelinating diseases and
infections.
Additional file
Additional file 1: Table S1. Pearson r correlation analysis of liver
chemokine mRNA in saline-, XPro1595- and etanercept-treated mice six
hours, 24 hours and five days after focal cerebral ischemia.
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